Tag: Biocartis

PRESS RELEASE: 13 May 2022, 17:40 CEST Results of the Annual Shareholders’ Meeting held on 13 May 2022 Mechelen, Belgium, 13 May 2022 – Biocartis Group NV (the ‘Company’ or ‘Biocartis’), an ...

PRESS RELEASE: 4 May 2022, 07:00 CEST New Study Led by Memorial Sloan Kettering Cancer Center (NY, US) Shows Idylla™ GeneFusion Assay Enables More Rapid Screening of Targetable Fusions Compared to Routine ...

PRESS RELEASE: REGULATED INFORMATION 12 April 2022, 07:00 CEST Invitation to the Annual Shareholders’ Meeting Mechelen, Belgium, 12 April 2022 – Biocartis Group NV (the ‘Company’ or ‘Biocartis’), an innovative molecular ...

PRESS RELEASE: REGULATED INFORMATION24 February 2022, 07:00 CET BIOCARTIS ANNOUNCES 2021 RESULTS AND 2022 OUTLOOK Mechelen, Belgium, 24 February 2022 – Biocartis Group NV (the ‘Company’ or ‘Biocartis’), an innovative molecular ...

PRESS RELEASE: REGULATED INFORMATION 17 February 2022, 07:00 CET BIOCARTIS ANNOUNCES 2021 FULL YEAR RESULTS ON 24 FEBRUARY 2022 Mechelen, Belgium, 17 February 2022 – Biocartis Group NV (the ‘Company’ or ‘Biocartis’), ...

PRESS RELEASE: REGULATED INFORMATION                                                                                4 February 2022, 07:00 CET Disclosure of a transparency notification Mechelen, Belgium, 4 February 2022 – Biocartis Group NV (the ‘Company’ or ‘Biocartis’), an innovative molecular diagnostics ...

PRESS RELEASE: 25 January 2022, 07:00 CET Large UK Study Shows Rapid EGFR Testing with Idylla™ Alongside NGS Has Potential to Enhance Lung Cancer Patient Health Outcomes Lung cancer accounts for ...

PRESS RELEASE: 9 December 2021, 07:00 CET Biocartis’ Idylla™ SARS-CoV-2 testing Successfully Detects Omicron Variant Mechelen, Belgium, 9 December 2021 – Biocartis Group NV (the ‘Company’ or ‘Biocartis’), an innovative molecular diagnostics ...

PRESS RELEASE: REGULATED INFORMATION                                                      ...